MedPath
HSA Approval

DOCEHOPE Concentrate for Solution for Infusion 20 mg/ ml

SIN16943P

DOCEHOPE Concentrate for Solution for Infusion 20 mg/ ml

DOCEHOPE Concentrate for Solution for Infusion 20 mg/ ml

February 7, 2024

GLENMARK PHARMACEUTICALS SINGAPORE PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantGLENMARK PHARMACEUTICALS SINGAPORE PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

INFUSION, SOLUTION CONCENTRATE

INTRAVENOUS

Medical Information

L01CD02

docetaxel

Manufacturer Information

GLENMARK PHARMACEUTICALS SINGAPORE PTE. LTD.

Glenmark Generics S.A.

Active Ingredients

Docetaxel Anhydrous

20 mg / ml

Docetaxel

Documents

Package Inserts

Docehope Concentrate for Solution for Infusion PI.pdf

Approved: February 7, 2024

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

DOCEHOPE Concentrate for Solution for Infusion 20 mg/ ml - HSA Approval | MedPath